GO:0061575 cyclin-dependent protein serine/threonine kinase activator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061575 describes a molecular function in which a protein binds to and increases the catalytic activity of a cyclin-dependent protein serine/threonine kinase (CDK).
• The defining biochemical event is the activation of a CDK by a separate activator subunit, often a cyclin or a cyclin-like protein, rather than the intrinsic kinase activity of the CDK itself.
• Classic examples include the activation of CDK7 by cyclin H within the CAK complex and the activation of CDK5 by neuron-specific activators p35 and p39.
• Viral proteins can also act as cyclin-dependent kinase activators, as shown for virus-encoded cyclins that activate cellular CDKs.
• Dysregulation of CDK activator function is linked to cancer, neurodegeneration, and ciliary length control, making these activators important experimental targets.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of activator-CDK interactions and their downstream phosphorylation events.
Description
Cyclin-dependent protein serine/threonine kinase activator activity (GO:0061575) is a molecular function that enables a protein to bind to and increase the activity of a cyclin-dependent protein serine/threonine kinase (CDK). This function is essential because CDKs are often catalytically inactive or weakly active on their own and require a separate activator subunit to achieve full kinase activity. The activator is typically a cyclin or a cyclin-like protein, but it can also be a viral protein that mimics cyclin function. The term is therefore central to understanding how CDK-driven phosphorylation events are controlled in time and space. Researchers study GO:0061575 to dissect cell-cycle regulation, neuronal signaling, and viral manipulation of host kinases. The function is defined by the activator's ability to bind and stimulate a CDK, not by the CDK's own catalytic activity, which distinguishes it from general kinase activator activities. Because CDK activation is a prerequisite for many phosphorylation cascades, this GO term is a key node in signaling networks relevant to cancer, neurodegeneration, and ciliary biology.
cyclin-dependent protein serine/threonine kinase activator activity At A Glance
| GO ID | GO:0061575 |
|---|---|
| GO term | cyclin-dependent protein serine/threonine kinase activator activity |
| Ontology | molecular_function |
| Synonym | cyclin-dependent protein kinase 5 activator activity |
| Definition | Binds to and increases the activity of a cyclin-dependent protein serine/threonine kinase. |
| Major function | Activates CDK catalytic activity by binding to the CDK and promoting substrate phosphorylation. |
| Example activators | Cyclin H for CDK7, p35/p39 for CDK5, viral cyclins for cellular CDKs. |
| Related kinases | CDK1, CDK2, CDK5, CDK7, CDK20. |
| Disease relevance | Cancer, neurodegeneration, ciliary disorders, viral pathogenesis. |
What Is GO:0061575?
GO:0061575, cyclin-dependent protein serine/threonine kinase activator activity, is defined as the molecular function of binding to and increasing the activity of a cyclin-dependent protein serine/threonine kinase. In practice, this means the gene product carrying this function acts as an activator subunit that associates with a CDK and enhances its ability to phosphorylate serine or threonine residues on substrate proteins. The activator itself is not necessarily a kinase; its role is to promote the catalytic function of the CDK partner. This function is distinct from the CDK's own kinase activity and from other types of kinase activator activities that do not specifically target CDKs.
Why Is cyclin-dependent protein serine/threonine kinase activator activity Important in Cell Biology?
GO:0061575 is important because CDK activation is a rate-limiting step in many phosphorylation-dependent processes, including cell-cycle progression, neuronal development, and ciliary length control. Without activator function, CDKs such as CDK7 and CDK5 cannot efficiently phosphorylate their substrates, which can disrupt transcription, cytoskeletal regulation, and neuronal signaling. The term also captures how viruses can hijack host CDKs through virus-encoded cyclin-like activators, a mechanism relevant to viral pathogenesis and oncogenesis. Because activator-CDK pairs are often tissue-specific or pathway-specific, they offer attractive targets for selective therapeutic intervention and for building precise experimental models.
• Defines a distinct molecular function that is essential for CDK catalytic activation in cell-cycle and transcriptional regulation.
• Explains how neuron-specific activators such as p35 and p39 drive CDK5 activity in the nervous system.
• Provides a mechanistic basis for viral manipulation of host CDKs through virus-encoded cyclins.
• Links CDK activation to ciliary length control via CDK20/LF2 and CDKL5.
• Is relevant to cancer because dysregulated CDK activation can drive uncontrolled proliferation.
• Is relevant to neurodegeneration because CDK5 hyperactivity contributes to tau phosphorylation.
• Supports the design of selective inhibitors that target activator-CDK interfaces rather than the CDK active site.
• Enables CRISPR-based dissection of activator function in disease models.
• Helps interpret phosphoproteomic changes that depend on activator availability.
• Guides research on transcription-related CDK7 activation by cyclin H.
What Happens During cyclin-dependent protein serine/threonine kinase activator activity?
Activator binding to the CDK
In simple terms: An activator protein attaches to a CDK enzyme.
The first step in GO:0061575 is the physical association of an activator protein with a cyclin-dependent protein serine/threonine kinase. This binding is often mediated by a conserved cyclin box or a cyclin-like fold in the activator, as seen for cyclins and viral cyclins. The interaction can occur in the cytoplasm or nucleus depending on the activator-CDK pair, and it is frequently regulated by phosphorylation or subcellular localization. For CDK5, the neuron-specific activators p35 and p39 bind to CDK5 and are required for its activity.
Conformational change and activation of the CDK
In simple terms: Binding changes the shape of the CDK so it can work better.
Upon activator binding, the CDK undergoes conformational changes that reposition key catalytic residues and the activation segment, thereby increasing its ability to transfer phosphate from ATP to serine or threonine residues on substrates. This activation is not merely a scaffolding effect; the activator directly increases the catalytic efficiency of the CDK. For CDK7, association with cyclin H is required for its CAK (CDK-activating kinase) activity, which in turn activates other CDKs. Similarly, CDK20/LF2 activation by a cyclin-like partner is needed for CDKL5 activation in ciliary length control.
Substrate phosphorylation by the activated CDK
In simple terms: The activated CDK then adds phosphate groups to target proteins.
Once activated, the CDK phosphorylates serine or threonine residues on specific substrate proteins. These substrates vary by CDK and activator context: CDK5 activated by p35 phosphorylates tau and other neuronal proteins, while CDK7 activated by cyclin H phosphorylates the C-terminal domain of RNA polymerase II and other CDKs. The specificity of phosphorylation is determined by the activator-CDK pair and by additional targeting factors. This step is the functional output of GO:0061575 and can be measured by phosphoproteomics or targeted phospho-antibodies.
Regulation and termination of activator function
In simple terms: The activation process can be turned on and off.
Activator function is dynamically regulated. For example, p35 can be cleaved to p25, which produces a more stable and mislocalized CDK5 activator associated with neurotoxicity. Viral cyclins can constitutively activate CDKs and evade normal cell-cycle checkpoints. In the ciliary context, CDK20/LF2-mediated activation of CDKL5 is required for flagellar length control, and its perturbation alters ciliary dynamics. These regulatory mechanisms ensure that CDK activation is transient and context-specific, and their disruption can lead to disease.
Key Genes Involved in GO:0061575 cyclin-dependent protein serine/threonine kinase activator activity
The following genes encode proteins that either carry cyclin-dependent protein serine/threonine kinase activator activity or are the CDK partners they activate, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCNH | Cyclin H, activator of CDK7 in the CAK complex | Studied for CDK7 activation and transcription regulation |
| CDK7 | CDK activated by cyclin H; phosphorylates CDKs and RNA Pol II | Key target for transcription and cell-cycle studies |
| CDK5 | Neuronal CDK activated by p35/p39 | Central to neurodegeneration and tau phosphorylation |
| CDK5R1 | p35, neuron-specific activator of CDK5 | Studied for CDK5 activation and tau phosphorylation |
| CDK5R2 | p39, neuron-specific activator of CDK5 | Studied for CDK5 regulation in neurons |
| CDK20 | CDK activated by cyclin-like partner; activates CDKL5 | Studied for ciliary length control |
| CDKL5 | Kinase activated by CDK20/LF2 | Studied for ciliary and neurodevelopmental roles |
| CCNA1 | Cyclin A1, activator of CDK1/2 | Studied for cell-cycle regulation |
| CCNB1 | Cyclin B1, activator of CDK1 | Studied for mitosis and checkpoint control |
| CCND1 | Cyclin D1, activator of CDK4/6 | Studied for G1 progression and cancer |
| CCNE1 | Cyclin E1, activator of CDK2 | Studied for S-phase entry and cancer |
| Viral cyclin (e.g., KSHV) | Virus-encoded cyclin that activates cellular CDKs | Studied for viral pathogenesis and oncogenesis |
| CDK1 | CDK activated by cyclins A/B | Studied for mitosis and cell-cycle control |
| CDK2 | CDK activated by cyclins A/E | Studied for DNA replication and cancer |
| CDK4 | CDK activated by cyclin D | Studied for G1 progression and cancer |
| CDK6 | CDK activated by cyclin D | Studied for G1 progression and cancer |
| Tau (MAPT) | Substrate of CDK5 activated by p35 | Studied for neurodegeneration and tau phosphorylation |
How Is cyclin-dependent protein serine/threonine kinase activator activity Regulated?
Cyclin-dependent protein serine/threonine kinase activator activity is regulated at multiple levels. Activator abundance and stability are controlled by transcription, translation, and ubiquitin-mediated degradation. Post-translational modifications of the activator or the CDK can modulate binding affinity and catalytic output. For CDK5, cleavage of p35 to p25 by calpain produces a constitutively active and mislocalized activator that is linked to neurotoxicity. Viral cyclins can bypass normal regulatory checkpoints and constitutively activate CDKs. In ciliary length control, CDK20/LF2-mediated activation of CDKL5 is required for proper flagellar length, and its perturbation alters ciliary dynamics. These regulatory layers ensure that CDK activation is transient and context-specific, and their disruption can contribute to disease.
cyclin-dependent protein serine/threonine kinase activator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCND1 | Cancer (G1 progression) | Knockout or overexpression in cancer cell lines |
| CDK5R1 (p35) | Neurodegeneration (tau phosphorylation) | Point mutation or knockout in neuronal cells |
| CDK20 | Ciliary length control | Knockout or knock-in in ciliated cells |
| Viral cyclin | Viral pathogenesis and oncogenesis | Overexpression in host cells |
| CDK7 | Transcription and cell-cycle regulation | Knockout or point mutation in cancer models |
Cancer and cell-cycle dysregulation
Dysregulated CDK activation is a hallmark of cancer. Cyclins such as cyclin D, E, A, and B act as activators of CDK4/6, CDK2, and CDK1, and their overexpression or stabilization can drive uncontrolled proliferation. Viral cyclins encoded by oncogenic viruses can activate cellular CDKs and contribute to transformation. Targeting activator-CDK interfaces is therefore an active area of therapeutic research.
Neurodegeneration and CDK5 hyperactivity
In neurons, CDK5 is activated by p35 and p39, and its dysregulation is linked to neurodegenerative processes. Cleavage of p35 to p25 produces a hyperactive CDK5 activator that phosphorylates tau at disease-relevant sites, contributing to neurofibrillary pathology. Peptides derived from p35 can inhibit CDK5 activity and reduce tau phosphorylation in transfected cells, highlighting the therapeutic potential of targeting this activator-CDK interaction.
Ciliary disorders and CDK20/LF2 signaling
CDK20/LF2 acts as an activator of CDKL5 to control flagellar length. Perturbation of this activator function alters ciliary dynamics, linking GO:0061575 to ciliary biology and potentially to ciliopathies. This emerging area highlights the importance of activator-CDK pairs beyond the classical cell cycle.
Viral pathogenesis
Herpes simplex virus type 2 infection has been shown to modulate cyclin-dependent kinase activity, and virus-encoded cyclins can directly activate cellular CDKs. This manipulation of GO:0061575 function can promote viral replication and contribute to pathogenesis.
From cyclin-dependent protein serine/threonine kinase activator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of activator function reduce CDK activity? | CRISPR knockout of the activator gene |
| Does a specific point mutation disrupt activator-CDK binding? | Point-mutation knock-in of the activator |
| Can a tagged activator be used to monitor localization? | Knock-in of an epitope tag |
| Does overexpression of the activator drive proliferation? | Overexpression of the activator in cell lines |
| Can activator-CDK interaction be inhibited by a peptide? | Peptide treatment in transfected cells |
| Does viral cyclin activate host CDKs? | Overexpression of viral cyclin in host cells |
How to Study the cyclin-dependent protein serine/threonine kinase activator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global changes in serine/threonine phosphorylation | Identifying CDK substrates upon activator perturbation |
| In vitro kinase assay | Direct catalytic activity of activator-CDK complexes | Testing activator function and inhibitors |
| Co-immunoprecipitation | Physical interaction between activator and CDK | Validating binding domains and mutations |
| Proximity labeling | Spatially restricted interactome of activator-CDK | Mapping activator interactions in cells |
| Live-cell imaging | Ciliary length and dynamics | Assessing CDK20/LF2 and CDKL5 function |
| CRISPR knockout screen | Gene requirement for CDK activation | Discovering novel activators |
| Western blot with phospho-antibodies | Site-specific phosphorylation of substrates | Measuring tau phosphorylation by CDK5 |
| qPCR / RNA-seq | Expression of activator and CDK genes | Correlating expression with activation state |
Phosphoproteomics and kinase assays
Because GO:0061575 ultimately increases CDK-mediated phosphorylation, phosphoproteomics and in vitro kinase assays are central methods. These approaches can quantify changes in substrate phosphorylation upon activator knockout or overexpression. For CDK5, tau phosphorylation is a well-established readout.
Co-immunoprecipitation and proximity labeling
Activator-CDK binding is a defining feature of GO:0061575, so co-immunoprecipitation and proximity labeling are used to detect and quantify these interactions. These methods can reveal whether a mutation disrupts binding and whether the activator associates with the CDK in a specific cellular compartment.
Live-cell imaging and ciliary assays
For ciliary roles of CDK20/LF2 and CDKL5, live-cell imaging and flagellar length measurements are used to assess activator function. These assays link molecular activation to cellular phenotypes such as ciliary length control.
CRISPR screens and functional genomics
CRISPR knockout screens can identify genes whose loss alters CDK activation or downstream phosphorylation. Such screens are useful for discovering novel activators or modifiers of GO:0061575 function.
How CRISPR Can Be Used to Study GO:0061575 cyclin-dependent protein serine/threonine kinase activator activity
Knockout
CRISPR knockout of activator genes such as CDK5R1 or CCNH can abolish CDK activation and reveal downstream phosphorylation defects. Knockout models are useful for testing whether a candidate activator is required for a specific CDK function in cells or organisms.
Point Mutation
Point mutations can be introduced into activator genes to disrupt specific binding interfaces or regulatory phosphorylation sites while preserving protein expression. Such models help distinguish binding-dependent activation from other functions of the activator.
Knock-in
Knock-in of epitope tags or fluorescent reporters into activator loci enables real-time tracking of activator localization and interaction with CDKs. This approach is valuable for studying dynamic activation events in live cells.
Overexpression
Overexpression of activators such as cyclins or viral cyclins can drive constitutive CDK activation and model disease states like cancer or viral pathogenesis. Overexpression models are also used to test whether increased activator levels are sufficient to transform cells.
How EDITGENE Supports cyclin-dependent protein serine/threonine kinase activator activity Research
Researchers studying cyclin-dependent protein serine/threonine kinase activator activity-related genes often need to determine whether a candidate gene is causally involved in CDK activation, substrate phosphorylation, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for cyclin-dependent protein serine/threonine kinase activator activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CCND1 Knockout HEK293 Cell Line | EDC07534 | Human | 595 | Details Get a Quote |
| CCND3 Knockout HEK293 Cell Line | EDJ-KQ285 | Human | 896 | Details Get a Quote |
| CCND2 Knockout HEK293 Cell Line | EDJ-KQ884 | Human | 894 | Details Get a Quote |
| CCNT1 Knockout HEK293 Cell Line | EDJ-KQ2254 | Human | 904 | Details Get a Quote |
| CCNT2 Knockout HEK293 Cell Line | EDJ-KQ3510 | Human | 905 | Details Get a Quote |
| CDK5R1 Knockout HEK293 Cell Line | EDJ-KQ5696 | Human | 8851 | Details Get a Quote |
| CDK5R2 Knockout HEK293 Cell Line | EDJ-KQ6411 | Human | 8941 | Details Get a Quote |
| CCNY Knockout HEK293 Cell Line | EDJ-KQ8328 | Human | 219771 | Details Get a Quote |
| CCNYL1 Knockout HEK293 Cell Line | EDJ-KQ11322 | Human | 151195 | Details Get a Quote |
| CCNYL1B Knockout HEK293 Cell Line | EDJ-KQ12825 | Human | 102724485 | Details Get a Quote |
| CCND3 Knockout HeLa Cell Line | EDJ-KQ17962 | Human | 896 | Details Get a Quote |
| CCNYL1B Knockout A-549 Cell Line | EDJ-KQ41963 | Human | 102724485 | Details Get a Quote |
| CCNYL1B Knockout HCT 116 Cell Line | EDJ-KQ41964 | Human | 102724485 | Details Get a Quote |
| CCNYL1B Knockout HeLa Cell Line | EDJ-KQ41965 | Human | 102724485 | Details Get a Quote |
| CCND3 Knockout A-549 Cell Line | EDJ-KQ18395 | Human | 896 | Details Get a Quote |
Displaying Records 1 To 15 Of 52 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About cyclin-dependent protein serine/threonine kinase activator activity
What is cyclin-dependent protein serine/threonine kinase activator activity?
It is a molecular function (GO:0061575) in which a protein binds to and increases the activity of a cyclin-dependent protein serine/threonine kinase (CDK).
What genes are involved in cyclin-dependent protein serine/threonine kinase activator activity?
Genes include CCNH (cyclin H), CDK5R1 (p35), CDK5R2 (p39), and viral cyclins, which activate CDKs such as CDK7 and CDK5.
What is the GO ID for cyclin-dependent protein serine/threonine kinase activator activity?
The GO ID is GO:0061575.
How does CDK5 activation by p35 work?
p35 binds to CDK5 and increases its kinase activity, enabling phosphorylation of substrates such as tau.
What diseases are linked to CDK activator dysfunction?
Dysregulation is linked to cancer, neurodegeneration, ciliary disorders, and viral pathogenesis.
Can viral proteins act as cyclin-dependent kinase activators?
Yes, virus-encoded cyclins can activate cellular CDKs and contribute to pathogenesis.
What is the role of cyclin H in CDK7 activation?
Cyclin H binds to CDK7 and is required for its CAK activity, which activates other CDKs and phosphorylates RNA Pol II.
How can I study cyclin-dependent protein serine/threonine kinase activator activity?
Common methods include phosphoproteomics, kinase assays, co-immunoprecipitation, and CRISPR knockout models.
What is the synonym for GO:0061575?
The synonym is cyclin-dependent protein kinase 5 activator activity.
Is CDK20/LF2 an activator of CDKL5?
Yes, CDK20/LF2 activates CDKL5 to control flagellar length.
Conclusion
Cyclin-dependent protein serine/threonine kinase activator activity (GO:0061575) is a fundamental molecular function that governs the activation of CDKs, which in turn control cell-cycle progression, transcription, neuronal signaling, and ciliary dynamics. The function is defined by the activator's ability to bind and stimulate a CDK, and it is carried out by diverse proteins including cyclins, p35/p39, and viral cyclins. Dysregulation of this activity is implicated in cancer, neurodegeneration, and ciliary disorders, making it a compelling target for basic and translational research. CRISPR-based models from EDITGENE enable precise dissection of activator-CDK interactions and their downstream effects, accelerating discovery in this important area.
References
- 1. Jung JU et al.. 1994. Virus-encoded cyclin.. Mol Cell Biol 14(11):7235-44 PMID: 7935438
- 2. Hou Y et al.. 2025. Activation of the ciliary kinase CDKL5 is mediated by the cyclin-dependent kinase CDK20/LF2 to control flagellar length.. PLoS Biol 23(12):e3003560 PMID: 41385589
- 3. Clarke PR. 1995. Cyclin-dependent kinases. CAK-handed kinase activation.. Curr Biol 5(1):40-2 PMID: 7697347
- 4. Shuttleworth J. 1995. The regulation and functions of cdk7.. Prog Cell Cycle Res 1:229-40 PMID: 9552366
- 5. Lew J et al.. 1994. A brain-specific activator of cyclin-dependent kinase 5.. Nature 371(6496):423-6 PMID: 8090222
- 6. Zheng YL et al.. 2002. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.. Eur J Biochem 269(18):4427-34 PMID: 12230554
- 7. Tang D et al.. 1996. Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators.. Prog Cell Cycle Res 2:205-16 PMID: 9552397
- 8. Hossain A et al.. 1997. Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.. J Gen Virol 78 ( Pt 12):3341-8 PMID: 9400986
